Inflamed moods: a review of the interactions between inflammation and mood disorders
Mood disorders have been recognized by the World Health Organization (WHO) as the
leading cause of disability worldwide. Notwithstanding the established efficacy of …
leading cause of disability worldwide. Notwithstanding the established efficacy of …
Novel therapeutic targets in depression: minocycline as a candidate treatment
JK Soczynska, RB Mansur, E Brietzke… - Behavioural brain …, 2012 - Elsevier
Mood disorders are marked by high rates of non-recovery, recurrence, and chronicity, which
are insufficiently addressed by current therapies. Several patho-etiological models have …
are insufficiently addressed by current therapies. Several patho-etiological models have …
Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug …
In the past two decades a trickle of manuscripts examining the non-neuronal central nervous
system immune consequences of the drugs of abuse has now swollen to a significant body …
system immune consequences of the drugs of abuse has now swollen to a significant body …
Cognitive dysfunction in depression–pathophysiology and novel targets
Major depressive disorder (MDD) is associated with cognitive dysfunction encompassing
several domains, including memory, executive function, processing speed and attention …
several domains, including memory, executive function, processing speed and attention …
Minocycline: therapeutic potential in psychiatry
Pharmacological interventions to treat psychiatric illness have previously focused on
modifying dysfunctional neurotransmitter systems to improve symptoms. However, imperfect …
modifying dysfunctional neurotransmitter systems to improve symptoms. However, imperfect …
Indoleamine-2, 3-dioxygenase/kynurenine pathway as a potential pharmacological target to treat depression associated with diabetes
Diabetes is a chronic disease associated with depression whose pathophysiological
mechanisms that associate these conditions are not fully elucidated. However, the activation …
mechanisms that associate these conditions are not fully elucidated. However, the activation …
Minocycline attenuates bone cancer pain in rats by inhibiting NF-κB in spinal astrocytes
Z Song, B **ong, X Guan, F Cao, A Manyande… - Acta Pharmacologica …, 2016 - nature.com
Aim: To investigate the mechanisms underlying the anti-nociceptive effect of minocycline on
bone cancer pain (BCP) in rats. Methods: A rat model of BCP was established by inoculating …
bone cancer pain (BCP) in rats. Methods: A rat model of BCP was established by inoculating …
Putative neuroprotective agents in neuropsychiatric disorders
S Dodd, M Maes, G Anderson, OM Dean… - Progress in Neuro …, 2013 - Elsevier
In many individuals with major neuropsychiatric disorders including depression, bipolar
disorder and schizophrenia, their disease characteristics are consistent with a …
disorder and schizophrenia, their disease characteristics are consistent with a …
Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA
N Granado, S Ares-Santos, I Oliva, ED Martin… - Neurobiology of …, 2011 - Elsevier
Methamphetamine (METH) and 3, 4-methylenedioxymethamphetamine (MDMA),
amphetamine derivatives widely used as recreational drugs, induce similar neurotoxic …
amphetamine derivatives widely used as recreational drugs, induce similar neurotoxic …
Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the …
M Angoa‐Pérez, MJ Kane… - Journal of …, 2012 - Wiley Online Library
J. Neurochem.(2012) 120, 1097–1107. Abstract Mephedrone (4‐methylmethcathinone) is a
β‐ketoamphetamine with close structural analogy to substituted amphetamines and …
β‐ketoamphetamine with close structural analogy to substituted amphetamines and …